Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked faithfully but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set away what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire interview which I came away with an inadequate opinion of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise as well as linked intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and also the first brand new drug program endorsement ($five million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and many indications, it’s this single therapies and a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease types, multiple delivering presentations and multiple publications.

Can all of it be smoke and mirrors? That’s a question I have been asking myself through the very start of the interest of mine in this particular company. Judging by way of the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a classic battleground, or possibly some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *